Table II.

Serum HSP-60, CHI3L1 and IGFBP-2 levels in the different groups (difference was calculated by Mann-Whitney U test).

	Serum HSP60 (ng/ml)			Serum CHI3L1 (ng/ml)			Serum IGFBP-2 (ng/ml)
Variable	Median	25–75% percentile	P-value	Median	25–75% percentile	P-value	Median	25–75% percentile	p-value
Age (n=97), years									0.289
≤55 (n=24)	0.51	0.36–1.02	0.878	125.0	93.0–227.5	0.025a	551.3	373.8–843.6
>55 (n=73)	0.51	0.34–0.85		195.5	125.3–609.0		634.9	435.6–1026.0
Sex,									0.870
Female (n=37)	0.52	0.35–1.19	0.329	153.0	78.0–384.0	0.114	622.9	377.5–1006.0
Male (n=60)	0.45	0.34–0.82		194.5	112.8–593.5		613.4	448.5–955.3
Primary tumor localization
Right colon (n=20) (caecum,   ascendens, transversum)	0.56	0.38–1.13	0.367a >0.99 vs. leftb	211.0	113.3–573.3	.179a >0.99 vs. leftb	578.9	290.0–725.4	0.322a 0.401 vs. leftb
Left colon (n=50) (descendens, sigmoideum, rectosigma)	0.52	0.38–1.10	0. 571 vs. rectumb	190.5	106.5–593.5	0.227 vs. rectumb	639.3	447.0–1029.0	>0.99 vs. rectumb
Sigmoideum, rectosigma, rectum (n=27)	0.46	0.31–0.87	0.754 vs. rightb	127.0	73.0–334.0	0.512 vs. rightb	677.2	404.1–975.0	0.817 vs. rightb
Degree of differentiation
Well or moderate (n=75)	0.50	0.35–0.78	0.307	188.0 166.0	105.0–592.0	0.410	613.4	435.5–954.0	0.743
Poorly (n=21)	0.63	0.33–1.21			92.5–568.5		714.0	374.9–1204.0
Primary tumor
Presence (n=20)	0.64	0.45–1.28	0.039a	181.5	119.8–898.8	0.214	869.1	432.0–1063.0	0.190
Absence (n=77)	0.46	0.34–0.77		177.0	99.0–402.0		565.7	424.0–913.2
Liver metastases
Presence (n=64)	0.52	0.36–1.20	0.217	180.0	102.0–628.5	0.568	613.4	435.6–1035.0	0.328
Absence (n=33)	0.43	0.34–0.62		177.0	100.0–278.0		608.3	417.2–851.1
Lung metastases
Presence (n=31)	0.42		0.010a	165.0	96.0–221.0	0.132	551.3	436.0–743.1	0.300
Absence (n=66)	0.52			188.0	110.3–604.5		677.2	413.5–1031.0

^aKruskal-Wallis test

^bMann Whitney U with Bonferroni's correction. HSP60, heat shock protein 60; CHI3L1, chitinase-3-like protein 1; IGFBP-2, insulin-like growth factor binding protein 2, CEA, carcinoembryonic antigen.